CRNX - Crinetics Pharmaceuticals GAAP EPS of -$0.73 misses by $0.17 revenue of $3.13M misses by $2.07M
Crinetics Pharmaceuticals press release (NASDAQ:CRNX): Q1 GAAP EPS of -$0.73 misses by $0.17. Revenue of $3.13M misses by $2.07M. Unrestricted cash, cash equivalents and investments totaled $319.7 million as of March 31, 2022, compared to $333.7 million as of December 31, 2021.
For further details see:
Crinetics Pharmaceuticals GAAP EPS of -$0.73 misses by $0.17, revenue of $3.13M misses by $2.07M